This company has shut down. Cardea Bio is no longer operating — its last tracked round was a Grant in 2022.
Explore the Startup GraveyardCardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Cardea Bio has raised $1.1M in total funding. The most recent round was Grant. The last funding was announced in May 2022.
Cardea Bio's investors include Bill & Melinda Gates Foundation, Foothill Ventures, Agilent Technologies, Taihill Venture, Alexandria Venture Investments.
Cardea Bio is headquartered in San Diego, United States.
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Cardea Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardea Bio — Funding & Investors." VCBacked, May 3, 2022, https://www.vcbacked.co/company/cardea-bio. Accessed July 19, 2026.
VCBacked. (2022). Cardea Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cardea-bio
{{cite web |title=Cardea Bio — Funding & Investors |url=https://www.vcbacked.co/company/cardea-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated